Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared to harvested saphenous veins at one year.
The data have been presented at the Netherlands Vascular Biology meeting organized by the Dutch Endothelial Biology Society – DEBS on March 10 and 11.
In the trial, the restorative XABG graft showed a more uniform profile and better flow compared to saphenous veins. Explant analysis revealed advanced healing, with a highly vascularized neo-tissue and evidence of mid graft endothelialization confirming the ongoing restorative process, and provided essential safety data. The XABG graft is currently in clinical trials.
“A restorative CABG device has the potential to offer a solution to a persistent unmet clinical need. The XABG trial results to date are very encouraging,”
said Martijn Cox, Xeltis Co-Founder and Chief Technology Officer.
Coronary Artery Bypass Graft (CABG) is the standard of care in multiple blood vessel occlusion/narrowing. It is normally performed by harvesting patient’s own veins, an additional surgery that may lead to pain and infections.
On average, around 20 percent of veins occlude by the end of the first year after CABG surgery. Synthetic grafts are currently not available. Heart attack is responsible for half of all cardiovascular deaths.